SM — 2mg/ 5mg/ 10mg

Selective GLP-1 Receptor Agonist | Targeted Appetite Suppression, Gastric Motility Regulation & Glycemic Balance

Overview:
SM (Semaglutide) is a long-acting synthetic peptide designed to function as a selective Glucagon-like Peptide-1 (GLP-1) receptor agonist. Featuring a modified amino acid structure with a fatty acid side-chain, SM binds with high affinity to GLP-1 receptors in the hypothalamus and gastrointestinal tract. It enhances glucose-dependent insulin secretion, inhibits inappropriate glucagon release, delays gastric emptying, and regulates central satiety signaling to drive significant body recomposition and glucose management.

This product is supplied as a sterile lyophilized powder in 2mg, 5mg, and 10mg multi-dose vial configurations and requires reconstitution prior to use.

Traditional short-acting GLP-1 analogues require frequent daily dosing due to rapid enzymatic degradation by Dipeptidyl Peptidase-4 (DPP-4). SM is structurally engineered with albumin-binding modifications that resist DPP-4 cleavage, extending its elimination half-life to approximately 7 days for sustained weekly administration.

By modulating hypothalamic hunger centers and slowing gastrointestinal transit time, SM effectively reduces caloric intake while improving insulin sensitivity. Offered in 2mg, 5mg, and high-yield 10mg multi-dose vials, this range provides flexible options for both standard step-up titration protocols and extended maintenance cycles.

• Potent Satiety & Appetite Suppression: Targets central nervous system satiety pathways to decrease overall appetite and curb food cravings.
• Delayed Gastric Emptying: Slows the rate at which food leaves the stomach, prolonging feelings of fullness and smoothing post-meal glucose spikes.
• Glucose-Dependent Insulin Release: Stimulates insulin secretion exclusively when blood glucose levels are elevated, minimizing hypoglycemia risk.
• Visceral & Subcutaneous Fat Loss: Drives sustainable caloric deficit conditions leading to targeted body fat reduction and lean mass retention.
• Extended 7-Day Half-Life: Resists DPP-4 degradation, allowing for consistent therapeutic levels with once-weekly dosing.

1. Reconstitute using Bacteriostatic Water (BAC).
2. Example: Add 2.0 mL of BAC Water to a 2mg or 5mg vial for a standard concentration, or 2.0 mL to 4.0 mL of BAC Water to a 10mg vial depending on desired syringe unit math.
3. Inject the BAC water slowly along the inner glass wall—do not squirt directly onto the lyophilized powder cake.
4. Gently swirl (do not shake) until the white powder dissolves completely into a clear, colorless liquid.
5. Store reconstituted SM in the refrigerator at 2°C – 8°C (36°F – 46°F) and use within 28 days.

For exact dose conversions and liquid volume planning, use our Reconstitution Calculator on the website.

Starting Titration Dose: 0.25 mg administered once weekly for the first 4 weeks to establish gastrointestinal tolerance.

Escalation Protocol: Increase dose incrementally (e.g., to 0.5 mg, 1.0 mg, up to 2.4 mg) every 4 weeks based on individual tolerance and target research objectives.

Administration Site: Subcutaneous injection once weekly into the lower abdomen, upper arm, or outer thigh (rotate sites regularly).

Protocol Duration: Cycles typically run 12 to 24+ weeks with gradual dose escalation.

Monitoring & Considerations:

• Common Considerations: Temporary gastrointestinal adaptation effects such as mild nausea, abdominal fullness, or altered bowel habits during initial titration steps.
• Monitoring: Periodically evaluate baseline body composition metrics, fasting blood glucose, and hydration status.
• Contraindications: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).